The history and status of dopamine cell therapies for Parkinson's disease
BioEssays · 2024
DOI: 10.1002/bies.202400118 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioEssays, 2024. Verfasst von Roger A Barker und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neurosciences and Cambridge Stem Cell Institute, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, U…. Hauptthemen laut MEDLINE: Parkinson Disease, Dopaminergic Neurons. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU FP7, Cure Parkinson's, NIHR Cambridge Biomedical Research Centre.
Abstract (Originalsprache)
Parkinson's disease (PD) is characterized by the loss of the dopaminergic nigrostriatal pathway which has led to the successful development of drug therapies that replace or stimulate this network pharmacologically. Although these drugs work well in the early stages of the disease, over time they produce side effects along with less consistent clinical benefits to the person with Parkinson's (PwP). As such there has been much interest in repairing this pathway using transplants of dopamine neurons. This work which began 50 years ago this September is still ongoing and has now moved to first in human trials using human pluripotent stem cell‐derived dopaminergic neurons. The results of these trials are eagerly awaited although proof of principle data has already come from trials using human fetal midbrain dopamine cell transplants. This data has shown that developing dopamine cells when transplanted in the brain of a PwP can survive long term with clinical benefits lasting decades and with restoration of normal dopaminergic innervation in the grafted striatum. In this article, we discuss the history of this field and how this has now led us to the recent stem cell trials for PwP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Neurosciences and Cambridge Stem Cell Institute, John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK.
- Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.
- Department of Clinical Sciences Lund, Lund Stem Cell Center and Division of Neurology, Lund University, Lund, Sweden.
ORCID-Profile: Roger A Barker
Förderung
- EU FP7
- Cure Parkinson's
- NIHR Cambridge Biomedical Research Centre
- New York Stem Cell Foundation
- Swedish Research Council
- Swedish Brain Foundation
- Novo Nordisk A/S, the Swedish Research Council
- European Research Council
Zitieren
APA
Barker, R. A., Björklund, A., & Parmar, M. (2024). The history and status of dopamine cell therapies for Parkinson's disease. BioEssays. https://doi.org/10.1002/bies.202400118
Vancouver
Barker RA, Björklund A, Parmar M. The history and status of dopamine cell therapies for Parkinson's disease. BioEssays. 2024. doi:10.1002/bies.202400118
BibTeX
@article{Barker2024,
author = {Barker, Roger A and Björklund, Anders and Parmar, Malin},
title = {The history and status of dopamine cell therapies for Parkinson's disease},
journal = {BioEssays},
year = {2024},
doi = {10.1002/bies.202400118}
}
EUVIMED